Difference between revisions of "Dabigatran reversal"

 
(11 intermediate revisions by 6 users not shown)
Line 5: Line 5:
 
==Mild Bleeding==
 
==Mild Bleeding==
 
*Local control measures: direct pressure
 
*Local control measures: direct pressure
*Delay next 1-2 doses OR discontinue (as appropriate)
+
*Delay next 1-2 doses '''OR''' discontinue (as appropriate)
  
==Moderate-Severe Bleeding==
+
==[[hemorrhage|Moderate-Severe Bleeding]]==
 
*Local control measures: direct pressure/surgical intervention
 
*Local control measures: direct pressure/surgical intervention
*Resuscitate with intravenous fluid and / blood products
+
*Resuscitate with intravenous [[IVF|fluid]] and / [[blood products]]
 
*Oral [[charcoal]] administration ''if drug taken <2 hours before presentation''
 
*Oral [[charcoal]] administration ''if drug taken <2 hours before presentation''
*Hemodialysis will remove ~60% of drug taken over prior 2-3 hours
+
*[[Hemodialysis]] will remove ~60% of drug taken over prior 2-3 hours
 +
*Consider [[Idarucizumab]] ([[Praxbind]]): 5 grams IV
  
==Life-Threatening Bleeding==
+
==[[hemorrhage|Life-Threatening Bleeding]]==
All of the above PLUS
+
*[[Idarucizumab]] (Praxbind): 5 grams IV
 +
 
 +
In addition, consider above PLUS
 
*Consider FEIBA<ref>Dager WE, Gosselin RC, Roberts AJ. "Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity". Crit Care Med. 2013 May;41(5):e42-6.</ref>
 
*Consider FEIBA<ref>Dager WE, Gosselin RC, Roberts AJ. "Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity". Crit Care Med. 2013 May;41(5):e42-6.</ref>
 
*Consider Recombinant Factor VIIa (no good data)
 
*Consider Recombinant Factor VIIa (no good data)
 
*Consider [[Prothrombin Complex Concentrate|Kcentra]] (PCC): 50 IU/kg IV bolus<ref>Eerenberg ES, et al. "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A randomized, placebo-controlled, crossover study in healthy subjects".  Circulation. 2011 Sep 6.</ref>
 
*Consider [[Prothrombin Complex Concentrate|Kcentra]] (PCC): 50 IU/kg IV bolus<ref>Eerenberg ES, et al. "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A randomized, placebo-controlled, crossover study in healthy subjects".  Circulation. 2011 Sep 6.</ref>
 +
*Consider Tranexamic acid
  
 
==See Also==
 
==See Also==
 
*[[Coagulopathy (Main)]]
 
*[[Coagulopathy (Main)]]
 +
*[[Idarucizumab]]
 +
*[[Anticoagulant reversal for life-threatening bleeds]]
  
==Source==
+
==References==
*Hennepin County Guidelines
 
*University of Utah Healthcare Thrombosis Service Guidelines
 
 
 
 
<references/>
 
<references/>
  
 
[[Category:Heme/Onc]]
 
[[Category:Heme/Onc]]
[[Category:Drugs]]
+
[[Category:Pharmacology]]

Latest revision as of 00:18, 1 October 2019

Background

  • If aPTT is <1.5 x control, it is unlikely that significant drug effect is present
  • Thrombin Time (TT) is most sensitive; normal TT excludes presence of significant dabigatran

Mild Bleeding

  • Local control measures: direct pressure
  • Delay next 1-2 doses OR discontinue (as appropriate)

Moderate-Severe Bleeding

  • Local control measures: direct pressure/surgical intervention
  • Resuscitate with intravenous fluid and / blood products
  • Oral charcoal administration if drug taken <2 hours before presentation
  • Hemodialysis will remove ~60% of drug taken over prior 2-3 hours
  • Consider Idarucizumab (Praxbind): 5 grams IV

Life-Threatening Bleeding

In addition, consider above PLUS

  • Consider FEIBA[1]
  • Consider Recombinant Factor VIIa (no good data)
  • Consider Kcentra (PCC): 50 IU/kg IV bolus[2]
  • Consider Tranexamic acid

See Also

References

  1. Dager WE, Gosselin RC, Roberts AJ. "Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity". Crit Care Med. 2013 May;41(5):e42-6.
  2. Eerenberg ES, et al. "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A randomized, placebo-controlled, crossover study in healthy subjects". Circulation. 2011 Sep 6.